Gross profits of Swedish biopharmaceutical company Sobi increased every year since 2011. The increase was especially significant during the latest years of the observed period. In 2020, the gross profit of Sobi was more than 12 billion Swedish kronor for the first time. The company's full name is Swedish Orphan Biovitrum AB. Sobi is specialized on the treatment of rare diseases.
Gross profit of Sobi from 2009 to 2020
(in million SEK)